ARYA Atherosclerosis Journal

Current Issue

By Issue

By Author

By Subject

Author Index

Keyword Index

About Journal

Aims and Scope

Editorial Board

Publication Ethics

Indexing and Abstracting

Related Links

FAQ

Peer Review Process

Journal Metrics

News

Precision medicine and metabolic syndrome

Document Type : Review Article

Authors

1 Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

2 Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.

3 Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

4 Hypertension Research Center, Cardiovascular Research Institute, Isfahan University of Medicine Sciences, Isfahan, Iran

5 Laboratory Quality Advisor/Technical Writer at COLA Resources Inc., Washington, Columbia, USA

6 Health Sciences Building, Central Michigan University, Mount Pleasant, MI, USA

10.22122/arya.2022.26215

Abstract

Metabolic syndrome (MetS) is one of the most important health issues around the world and a major risk factor for both type 2 diabetes mellitus (T2DM) and cardiovascular diseases. The etiology of MetS is determined by the interaction between genetic and environmental factors. Effective prevention and treatment of MetS notably decreases the risk of its complications such as diabetes, obesity, hypertension, and dyslipidemia. According to recent genome-wide association studies, multiple genes are involved in the incidence and development of MetS. The presence of particular genes which are responsible for obesity and lipid metabolism, affecting insulin sensitivity and blood pressure, as well as genes associated with inflammation, can increase the risk of MetS. These molecular markers, together with clinical data and findings from proteomic, metabolomic, pharmacokinetic, and other methods, would clarify the etiology and pathophysiology of MetS and facilitate the development of personalized approaches to the management of MetS. The application of personalized medicinebased on susceptibility identified genomes would help physicians recommend healthier lifestyles and prescribe medications to improve various aspects of health in patients with MetS. In recent years, personalized medicine by genetic testing has helped physicians determine genetic predisposition to MetS, prevent the disease by behavioral, lifestyle-related, or therapeutic interventions, and detect, diagnose, treat, and manage the disease. Clinically, personalized medicine is providing effective strategies for the prevention and treatment of MetS by reducing the time, cost, and failure rate of pharmaceutical clinical trials. It is also eliminating trial-and-error inefficiencies that inflate health care costs and undermine patient care.

Keywords

References
  1. Roche HM, Phillips C, Gibney MJ. The metabolic syndrome: The crossroads of diet and genetics. Proc Nutr Soc 2005; 64(3): 371-7.
  2. Xu H, Li X, Adams H, Kubena K, Guo S. Etiology of metabolic syndrome and dietary intervention. Int J Mol Sci 2018; 20(1).
  3. Amirkalali B, Fakhrzadeh H, Sharifi F, Kelishadi R, Zamani F, Asayesh H, et al. Prevalence of metabolic syndrome and its components in the Iranian adult population: A systematic review and meta-analysis. Iran Red Crescent Med J 2015; 17(12): e24723.
  4. Dalle GR, Calugi S, Centis E, Marzocchi R, El GM, Marchesini G. Lifestyle modification in the management of the metabolic syndrome: Achievements and challenges. Diabetes Metab Syndr Obes 2010; 3: 373-85.
  5. Mozaffarian D, Hao T, Rimm EB, Willett WC, Hu FB. Changes in diet and lifestyle and long-term weight gain in women and men. N Engl J Med 2011; 364(25): 2392-404.
  6. Davis SN. Contemporary strategies for managing cardiometabolic risk factors. J Manag Care Pharm 2006; 12(1 Suppl): S4-S9.
  7. Alshehri AM. Metabolic syndrome and cardiovascular risk. J Family Community Med 2010; 17(2): 73-8.
  8. Deedwania PC, Volkova N. Current treatment options for the metabolic syndrome. Curr Treat Options Cardiovasc Med 2005; 7(1): 61-74.
  9. Lee L, Sanders RA. Metabolic syndrome. Pediatr Rev 2012; 33(10): 459-66.
  10. Williams T. Metabolic syndrome: Nonalcoholic fatty liver disease. FP Essent 2015; 435: 24-9.
  11. Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract 2014; 2014: 943162.
  12. Gharipour M, Sadeghi M. Pivotal role of microRNA-33 in metabolic syndrome: A systematic review. ARYA Atheroscler 2013; 9(6): 372-6.
  13. Omran A, Elimam D, He F, Peng J, Yin F. Potential role of blood microRNAs as non-invasive biomarkers for early detection of asymptomatic coronary atherosclerosis in obese children with metabolic syndrome. Med Hypotheses 2012; 79(6): 889-93.
  14. Goguet-Rubio P, Klug RL, Sharma DL, Srikanthan K, Puri N, Lakhani VH, et al. Existence of a strong correlation of biomarkers and mirna in females with metabolic syndrome and obesity in a population of west Virginia. Int J Med Sci 2017; 14(6): 543-53.
  15. Nichols GA, Brown JB. Higher medical care costs accompany impaired fasting glucose. Diabetes Care 2005; 28(9): 2223-9.
  16. Thompson D, Brown JB, Nichols GA, Elmer PJ, Oster G. Body mass index and future healthcare costs: A retrospective cohort study. Obes Res 2001; 9(3): 210-8.
  17. Monda KL, North KE, Hunt SC, Rao DC, Province MA, Kraja AT. The genetics of obesity and the metabolic syndrome. Endocr Metab Immune Disord Drug Targets 2010; 10(2): 86-108.
  18. Vargas T, Moreno-Rubio J, Herranz J, Cejas P, Molina S, Gonzalez-Vallinas M, et al. Genes associated with metabolic syndrome predict disease-free survival in stage II colorectal cancer patients. A novel link between metabolic dysregulation and colorectal cancer. Mol Oncol 2014; 8(8): 1469-81.
  19. Sigman M. Introduction: Personalized medicine: What is it and what are the challenges? Fertil Steril 2018; 109(6): 944-5.
  20. Vogenberg FR, Isaacson BC, Pursel M. Personalized medicine: Part 1: Evolution and development into theranostics. P T 2010; 35(10): 560-76.
  21. Vogenberg FR, Barash CI, Pursel M. Personalized medicine: Part 2: Ethical, legal, and regulatory issues. P T 2010; 35(11): 624-42.
  22. Jakka S, Rossbach M. An economic perspective on personalized medicine. The HUGO Journal 2013; 7(1): 1.
  23. Savoia C, Volpe M, Grassi G, Borghi C, Agabiti RE, Touyz RM. Personalized medicine-a modern approach for the diagnosis and management of hypertension. Clin Sci (Lond) 2017; 131(22): 2671-85.
  24. Guest FL, Guest PC. Point-of-care testing and personalized medicine for metabolic disorders. Methods Mol Biol 2018; 1735: 105-14.
  25. Shapiro H, Suez J, Elinav E. Personalized microbiome-based approaches to metabolic syndrome management and prevention. J Diabetes 2017; 9(3): 226-36.
  26. Quezada H, Guzman-Ortiz AL, Diaz-Sanchez H, Valle-Rios R, Aguirre-Hernandez J. Omics-based biomarkers: Current status and potential use in the clinic. Bol Med Hosp Infant Mex 2017; 74(3): 219-26.
  27. Sethi S, Brietzke E. Omics-based biomarkers: application of metabolomics in neuropsychiatric disorders. Int J Neuropsychopharmacol 2015; 19(3): yv096.
  28. Vargas AJ, Harris CC. Biomarker development in the precision medicine era: Lung cancer as a case study. Nat Rev Cancer 2016; 16(8): 525-37.
  29. Ferreira de Lima RL, Moretti-Ferreira D, Richieri-Costa A, Murray JC. Identity by descent and candidate gene mapping of Richieri-Costa and Pereira syndrome. Am J Med Genet A 2003; 122A(1): 56-8.
  30. Tofigh A, Suderman M, Paquet ER, Livingstone J, Bertos N, Saleh SM, et al. The prognostic ease and difficulty of invasive breast carcinoma. Cell Rep 2014; 9(1): 129-42.
  31. McShane LM, Polley MY. Development of omics-based clinical tests for prognosis and therapy selection: The challenge of achieving statistical robustness and clinical utility. Clin Trials 2013; 10(5): 653-65.
  32. Fenwick PH, Jeejeebhoy K, Dhaliwal R, Royall D, Brauer P, Tremblay A, et al. Lifestyle genomics and the metabolic syndrome: A review of genetic variants that influence response to diet and exercise interventions. Crit Rev Food Sci Nutr 2019; 59(13): 2028-39.
  33. Taylor JY, Kraja AT, de Las Fuentes L, Stanfill AG, Clark A, Cashion A. An overview of the genomics of metabolic syndrome. J Nurs Scholarsh 2013; 45(1): 52-9.
  34. Pollex RL, Hanley AJ, Zinman B, Harris SB, Khan HM, Hegele RA. Metabolic syndrome in aboriginal Canadians: Prevalence and genetic associations. Atherosclerosis 2006; 184(1): 121-9.
  35. Kraja AT, Chasman DI, North KE, Reiner AP, Yanek LR, Kilpelainen TO, et al. Pleiotropic genes for metabolic syndrome and inflammation. Mol Genet Metab 2014; 112(4): 317-38.
  36. Meirhaeghe A, Cottel D, Amouyel P, Dallongeville J. Association between peroxisome proliferator-activated receptor gamma haplotypes and the metabolic syndrome in French men and women. Diabetes 2005; 54(10): 3043-8.
  37. Zhou JM, Zhang M, Wang S, Wang BY, Han CY, Ren YC, et al. Association of the ADIPOQ Rs2241766 and Rs266729 polymorphisms with metabolic syndrome in the Chinese population: A meta-analysis. Biomed Environ Sci 2016; 29(7): 505-15.
  38. Yamada Y, Kato K, Hibino T, Yokoi K, Matsuo H, Segawa T, et al. Prediction of genetic risk for metabolic syndrome. Atherosclerosis 2007; 191(2): 298-304.
  39. Larifla L, Rambhojan C, Joannes MO, Maimaitiming-Madani S, Donnet JP, Marianne-Pepin T, et al. Gene polymorphisms of FABP2, ADIPOQ and ANP and risk of hypertriglyceridemia and metabolic syndrome in afro-caribbeans. PLoS One 2016; 11(9): e0163421.
  40. Gallagher CJ, Langefeld CD, Gordon CJ, Campbell JK, Mychaleckyj JC, Bryer-Ash M, et al. Association of the estrogen receptor-alpha gene with the metabolic syndrome and its component traits in African-American families: The Insulin Resistance Atherosclerosis Family Study. Diabetes 2007; 56(8): 2135-41.
  41. Yamada Y, Ichihara S, Kato K, Yoshida T, Yokoi K, Matsuo H, et al. Genetic risk for metabolic syndrome: Examination of candidate gene polymorphisms related to lipid metabolism in Japanese people. J Med Genet 2008; 45(1): 22-8.
  42. Love-Gregory L, Sherva R, Sun L, Wasson J, Schappe T, Doria A, et al. Variants in the CD36 gene associate with the metabolic syndrome and high-density lipoprotein cholesterol. Hum Mol Genet 2008; 17(11): 1695-704.
  43. Gonzalez-Sanchez JL, Martinez-Larrad MT, Saez ME, Zabena C, Martinez-Calatrava MJ, Serrano-Rios M. Endothelial nitric oxide synthase haplotypes are associated with features of metabolic syndrome. Clin Chem 2007; 53(1): 91-7.
  44. Russo P, Lauria F, Loguercio M, Barba G, Arnout J, Cappuccio FP, et al. -344C/T Variant in the promoter of the aldosterone synthase gene (CYP11B2) is associated with metabolic syndrome in men. Am J Hypertens 2007; 20(2): 218-22.
  45. Kraja AT, Vaidya D, Pankow JS, Goodarzi MO, Assimes TL, Kullo IJ, et al. A bivariate genome-wide approach to metabolic syndrome: STAMPEED consortium. Diabetes 2011; 60(4): 1329-39.
  46. Povel CM, Boer JM, Reiling E, Feskens EJ. Genetic variants and the metabolic syndrome: A systematic review. Obes Rev 2011; 12(11): 952-67.
  47. Shen H, Qi L, Tai ES, Chew SK, Tan CE, Ordovas JM. Uncoupling protein 2 promoter polymorphism -866G/A, central adiposity, and metabolic syndrome in Asians. Obesity (Silver Spring) 2006; 14(4): 656-61.
  48. Hegele RA, Connelly PW, Hanley AJ, Sun F, Harris SB, Zinman B. Common genomic variation in the APOC3 promoter associated with variation in plasma lipoproteins. Arterioscler Thromb Vasc Biol 1997; 17(11): 2753-8.
  49. Hegele RA, Harris SB, Hanley AJ, Cao H, Zinman B. G protein beta3 subunit gene variant and blood pressure variation in Canadian Oji-Cree. Hypertension 1998; 32(4): 688-92.
  50. Al-Attar SA, Pollex RL, Ban MR, Young TK, Bjerregaard P, Anand SS, et al. Association between the FTO rs9939609 polymorphism and the metabolic syndrome in a non-Caucasian multi-ethnic sample. Cardiovasc Diabetol 2008; 7: 5.
  51. Wang H, Dong S, Xu H, Qian J, Yang J. Genetic variants in FTO associated with metabolic syndrome: A meta- and gene-based analysis. Mol Biol Rep 2012; 39(5): 5691-8.
  52. Joy T, Lahiry P, Pollex RL, Hegele RA. Genetics of metabolic syndrome. Curr Diab Rep 2008; 8(2): 141-8.
  53. Jeong SW, Chung M, Park SJ, Cho SB, Hong KW. Genome-wide association study of metabolic syndrome in koreans. Genomics Inform 2014; 12(4): 187-94.
  54. Zhu Y, Zhang D, Zhou D, Li Z, Li Z, Fang L, et al. Susceptibility loci for metabolic syndrome and metabolic components identified in Han Chinese: a multi-stage genome-wide association study. J Cell Mol Med 2017; 21(6): 1106-16.
  55. Zabaneh D, Balding DJ. A genome-wide association study of the metabolic syndrome in Indian Asian men. PLoS One 2010; 5(8): e11961.
  56. Haydar S, Grigorescu F, Lautier C, Normand C, Hadi JC, Vintila M, et al. Association of ATF5 gene with metabolic syndrome and insulin resistance in Mediterranean populations. Diabetes 2018; 67(Suppl 1): 2410-Pub.
  57. Wang Z, Gerstein M, Snyder M. RNA-Seq: A revolutionary tool for transcriptomics. Nat Rev Genet 2009; 10(1): 57-63.
  58. Reumann S. Toward a definition of the complete proteome of plant peroxisomes: Where experimental proteomics must be complemented by bioinformatics. Proteomics 2011; 11(9): 1764-79.
  59. Ali I, Aboul-Enein HY, Singh P, Singh R, Sharma B. Separation of biological proteins by liquid chromatography. Saudi Pharm J 2010; 18(2): 59-73.
  60. Yang Y, Zhang S, Howe K, Wilson DB, Moser F, Irwin D, et al. A comparison of nLC-ESI-MS/MS and nLC-MALDI-MS/MS for GeLC-based protein identification and iTRAQ-based shotgun quantitative proteomics. J Biomol Tech 2007; 18(4): 226-37.
  61. Kentsis A, Monigatti F, Dorff K, Campagne F, Bachur R, Steen H. Urine proteomics for profiling of human disease using high accuracy mass spectrometry. Proteomics Clin Appl 2009; 3(9): 1052-61.
  62. Mischak H, Allmaier G, Apweiler R, Attwood T, Baumann M, Benigni A, et al. Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med 2010; 2(46): 46ps42.
  63. Adachi J, Kumar C, Zhang Y, Mann M. In-depth analysis of the adipocyte proteome by mass spectrometry and bioinformatics. Mol Cell Proteomics 2007; 6(7): 1257-73.
  64. Khan M, Joseph F. Adipose tissue and adipokines: The association with and application of adipokines in obesity. Scientifica (Cairo) 2014; 2014: 328592.
  65. Deng Y, Scherer PE. Adipokines as novel biomarkers and regulators of the metabolic syndrome. Ann N Y Acad Sci 2010; 1212: E1-E19.
  66. Zhou H, Xiao Y, Li R, Hong S, Li S, Wang L, et al. Quantitative analysis of secretome from adipocytes regulated by insulin. Acta Biochim Biophys Sin (Shanghai) 2009; 41(11): 910-21.
  67. Metz TO, Jacobs JM, Gritsenko MA, Fontes G, Qian WJ, Camp DG, et al. Characterization of the human pancreatic islet proteome by two-dimensional LC/MS/MS. J Proteome Res 2006; 5(12): 3345-54.
  68. Zhang A, Sun H, Wang X. Power of metabolomics in biomarker discovery and mining mechanisms of obesity. Obes Rev 2013; 14(4): 344-9.
  69. Wu N, Wang W, Yi M, Cheng S, Wang D. Study of the metabolomics characteristics of patients with metabolic syndrome based on liquid chromatography quadrupole time-of-flight mass spectrometry. Ann Endocrinol (Paris) 2018; 79(1): 37-44.

Lin E, Kuo PH, Liu YL, Yang AC, Tsai SJ. Detection of susceptibility loci on APOA5 and COLEC12 associated with metabolic syndrome using a genome-wide association study in a Taiwanese population. Oncotarget 2017; 8(55): 93349-59.

ARYA Atherosclerosis Journal
Volume 18, Issue 4
April 2022
Pages 1-10
Files
Share
How to cite
Statistics